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Abstract Congenital heart defects (CHD) are the most
common developmental errors in humans, affecting 8 out
of 1,000 newborns. Clinical diagnosis and treatment of
CHD has dramatically improved in the last decades. Hence,
the majority of CHD patients are now reaching reproduc-
tive age. While the risk of familial recurrence has been
evaluated in various population studies, little is known
about the genetic pathogenesis of CHD. In recent years
significant progress has been made in uncovering genetic
processes during cardiac development. Data from human
genetic studies in CHD patients indicate that the genetic
aetiology was presumably underestimated in the past.
Inherited mutations in genes encoding cardiac transcription
factors and sarcomeric proteins were found as an under-
lying cause for familial recurrence of non-syndromic CHD
in humans, in particular cardiac septal defects. Notably, the
cardiac phenotypes most frequently seen in mutation car-
riers are ostium secundum atrial septal defects (ASDII).
This review outlines experimental approaches employed
for the detection of CHD-related genes in humans and
summarizes recent findings in molecular genetics of con-
genital cardiac septal defects with an emphasis on ASDII.
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Introduction
Congenital heart defects (CHD) represent the most com-
mon inborn malformation and are estimated as a major
cause for prenatal birth losses. Despite the progress that has
been achieved in diagnostic and therapeutic strategies,
CHD still cause significant morbidity and mortality in
western populations. Yet, the survival of patients with
CHD has dramatically increased during the last 30 years,
mainly due to advances in cardiac surgery and interven-
tional procedures. More than 80% of patients with complex
inborn malformation are now reaching adulthood [38, 47].
Grown-ups with congenital heart disease (GUCH) are a
heterogeneous group of patients which are also predisposed
to age-related cardiac diseases such as coronary heart dis-
ease and heart failure. Therefore, adequate management of
GUCH patients require sophisticated medical treatment
from specialized paediatric and/or adult cardiologists.
Concerns of sufficient medical treatment were met by
scientific statements from cardiovascular societies [63] and
by the establishment of international guidelines [21, 72].
Yet, the growing number of GUCH patients who are
now reaching reproductive age also demands a better
understanding of genetic transmission, disease penetrance,
and risk of CHD recurrence. Recent human genetic find-
ings have gained novel insights into genetic aetiology of
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cardiac malformations by identifying single gene defects as a
pathogenic substrate for familial recurrence of CHD [11].
These studies have remarkably improved our understanding
of gene-related regulatory processes involved in human heart
development. Still, it appears that human CHD arise from a
multifactorial origin with complex interactions of genetic
and environmental factors. For clinicians treating patients
with CHD, any knowledge about a genetic aetiology is rel-
evant due to the following reasons: gene defects in regulatory
genes may also disrupt the development of other organ sys-
tems. Moreover, the risk of disease transmission should be
evaluated in GUCH patients with a desire to have children
and there may be other (asymptomatic) family members
warranting genetic or clinical characterization.
Cardiac development
CHD arise from perturbations of cardiac development during
embryogenesis. In the past years molecular mechanisms
underlying cardiac morphogenesis were studied in vivo by
the generation of gene-targeted animal models [34]. The
heart is composed of early progenitor cells from at least two
sources located in bilateral cardiogenic fields [13]. Migration
and fusion of myocardial and endocardial precursor cells
form a linear heart tube on day 20 of human development.
Rightward looping and chamber formation is followed by
development of the cardiac conductive tissue and coronary
vessels (days 28–32). During cardiac morphogenesis, dif-
ferent cell lineages must be tightly regulated to assure correct
localization and growth [69]. In fact, regulatory genes such
as transcription factors represent the key players in devel-
opmental processes. Transcription factors titrate the
expression of tissue specific genes and mediate molecular
responses on environmental stimuli. The important role of
gene expression regulation in cardiac development was
highlighted by the identification of inherited mutations in
transcription factors in families with CHD [11]. Meanwhile,
a large spectrum of mutations was found in a considerable
number of genes expressed in early cardiogenesis. Notably,
atrial septum secundum defect (ASDII) is among the most
frequently noted cardiac phenotypes found in mutation car-
riers with non-syndromic CHD.
ASDII: a model disease for genetic CHD
The formation of atrial septa is initiated at a late stage of
cardiac development (from day 60 onwards). The septum
primum grows from the roof of the primordial atrium
towards the endocardial cushion. Before the septum pri-
mum adnates with the cardiac atrioventricular cushion,
small perforations develop in the upper part of the septum
primum and subsequently fuse to the foramen secundum.
The foramen secundum supplies prenatal blood flow from
the right to the left atrium to bypass premature pulmonary
circulation. Normally, the foramen secundum is covered by
the atrial septum secundum which attaches to the septum
primum after birth. ASDII are a result of an insufficient
growth of the septum secundum, mostly located in the
fossa ovalis of the atrial septum. The clinical appearance of
patients with ASDII depends on the shunt volume.
Although ASDII is considered to be a non-severe CHD, it
is associated with a higher mortality when treated after the
third decade of life [56]. In most clinical centres, catheter-
guided device closure has become a standard treatment for
ASDII [62]. Yet, aetiology of ASDII remains unclear in the
majority of patients. While maternal exposure to environ-
mental risk factors predispose to ASDII [37, 87], a familial
risk is also well documented (MIM 607941) [15, 17, 59]. A
recent study included more than 18,000 subjects with CHD
from a Danish population and determined a recurrence risk
for isolated ASDII of approximately 7% [59]. These find-
ings are convergent with previous family studies on ASDII
recurrence [17]. CHD patients and family relatives har-
bouring transcription factor mutations frequently present
ASDII as an isolated cardiac phenotype. Intriguingly,
ASDII were also found in patients with cardiomyopathies
due to mutations in sarcomeric genes [14, 54] indicating
that regular growth of the septum secundum may be highly
vulnerable towards genetic perturbations. As most patients
with ASDII reach advanced age even when left untreated
[74], the clinical characterization of multiple affected
family relatives is feasible in the context of a genetic
workup. Given the high heterogeneity of genetic factors
contributing to ASDII, this CHD subtype may well suit as a
model disease for researching genetic pathogenesis of
inborn developmental defects of the heart.
Approaches to study the genetic basis of CHD
In spite of the tremendous progress that has been achieved
in the technology of gene analyses (including array-based
technologies, whole genome sequencing, etc.), the value of
a careful selection of appropriate probands cannot be
overestimated. All genetic investigations start off with the
identification of a well-defined phenotype in a proband or a
family. While genetic results are functionally analysed and
critically evaluated, the cardiac phenotypes often remain
too little discussed. Although ASDII may be considered as
a rather uncomplex lesion, it might be of interest if subtle
anomalies are over-represented among those defects rela-
ted to a genetic defect. We and others were able to show
that ‘‘swiss-cheese-like’’ ASDII (so-called cribriform
ASDII) or atrial septal aneurysms seem to be over-represented
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in patients harbouring single gene mutations [32, 54, 64, 65].
Genotype–phenotype associations, but among a larger num-
ber of patients, remain to be carried out in order to identify
gene specific phenotypes.
Experimental settings
Genetic approaches utilized to identify CHD-associated
gene defects are multifaceted and versatile. Nevertheless,
one may—for comprehensible reasons—distinguish three
different genetic techniques that have been successfully
employed in the past to unravel the genetic aetiology of
human CHD (Fig. 1). These types of analysis are now
described in the following three sections.
Pedigree-based linkage analyses
Pedigree-based linkage studies rely on large ‘‘informative’’
families with multiple affected and unaffected relatives.
Upon identification of phenotypes inherited in family rela-
tives, the construction of a pedigree allows determination of
the mode of Mendelian inheritance. Co-segregation of the
respective phenotype with specific chromosomal markers is
used to determine a chromosomal region in the proximity of
the underlying disease gene. Fine mapping of the disease-
related region may further reduce the number of potential
genes. Mutational analysis of plausible gene candidates
within this region may finally lead to the identification of
the causative mutation. While large numbers of chromo-
somal markers were necessary to securely assess segrega-
tion of genetic fragments in a kindred, geneticists are now
able to use genotyping arrays (the so-called ‘‘SNP-Chips’’)
for chromosomal mapping. Pedigree-based whole genome
linkage analyses were successfully employed to identify
novel genes related to familial ASDII. In fact, ASDII-
associated mutations cardiac transcription factors and sar-
comeric genes were first identified by use of pedigree-based
haplotype mapping [18, 24, 48, 73]. However, a major
obstacle of linkage analyses is the identification and
recruitment of large families including compliant relatives
with and without the disease phenotype.
Cytogenetic analyses
The second approach exploits chromosomal aberrations seen
in patients with syndromic CHD to identify CHD-relevant
genes. The most frequent syndromic disease with inborn
cardiac defects is the velocardiofacial or DiGeorge syn-
drome with an incidence of 1 out of 4,000 live births (OMIM
188400 and 192430). More than 90% of the patients with
DiGeorge syndrome show a microdeletion on chromosome
22q11 spanning 1.5–3 megabases [92]. Subsequent charac-
terization of genes mapped to the 22q11 locus resulted in
identification of Ufd1, a gene involved in the degradation of
ubiquitinated proteins in neural crest cells [91]. Moreover,
the cardiac transcription factor TBX1, which also maps to
22q11 was found as a key determinant for DiGeorge syn-
drome-associated heart defects [52]. Indeed, Yagi and
colleagues [90] found TBX1 mutations in patients with
DiGeorge phenotype, but without 22q11 microdeletion. The
development of comparative genomic hybridization (Array-
CGH) technology now allows a significantly higher reso-
lution of chromosomal imbalances when compared to the
microscopic fluorescent in situ hybridization (FISH) anal-
yses. Genetic imbalances (duplications, deletions or inver-
sions) of less than 5,000 base pairs can be detected by
Array-CGH. In recent investigations, this technology was
employed to explore sub-microscopic aberrations in
patients with syndromic CHD. Thienpont et al. [86] studied
60 patients with CHD and syndromic appearance by Array-
CGH and found a variety of small chromosomal imbalances
related to human CHD. Moreover, sub-microscopic aber-
rations could also be found in a number of CHD patients
with non-syndromic CHD [23]. Yet, functional conse-
quences of a large number of aberrations are still unclear,
and databases containing frequencies of non-pathogenic
imbalances (copy number variations = CNVs) in a general
population remain to be completed.
Fig. 1 Strategies for the identification of gene mutations associated
with CHD. The selection of potential gene candidates can be achieved
after identification of a chromosomal locus (kindred-based haplotype
mapping or cytogenetic abberations) or via a rationale based on other
experimental findings (candidate gene approach). Pathogenicity of
novel sequence variants should be evaluated by family study,
genotyping of adequate controls and functional assays
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Candidate gene analyses
The third approach is the disease gene or candidate gene
analysis. Mutational screenings of ASDII disease genes are
suitable to systematically assess the frequency of mutations
within one single gene in a predefined patient cohort.
Given the high heterogeneity of CHD-related gene muta-
tions (e.g. more than 50 different mutations were found in
TBX5), most mutational analyses include the whole coding
region of a disease gene in an attempt to find novel vari-
ants. Systematic disease gene analysis may lead to the
detection of mutational hot spots within a single gene or to
specific genotype–phenotype correlations. In contrast to
disease gene sequencing, candidate gene analyses aim to
investigate sequence alterations in genes which were not
previously described in relation to human CHD. Results
from gene-targeted rodent models indicate candidates that
may also play a role in human heart defects. As an example
Sperling and colleagues analysed the transcriptional mod-
ulator CITED2 based on the embryonic phenotype found in
knock-out mice [2] and identified a considerable number of
mutations in patients with cardiac septal defects [77]. The
identification of the first mutations in the human tran-
scription factor TBX20 related to CHD was also achieved
by a candidate gene approach [41]. Recent advances in
gene sequencing technology allow simultaneous analyses
of multiple genes in hundreds of CHD patients from
national registries and biobanks [76]. However, as the
number of patients and genes increase, the interpretation of
novel sequence variants in relation to the related phenotype
becomes a major challenge.
Cardiac transcription factors and human CHD
Transcription factors regulate cell lineage-specific gene
expression and are important factors in developmental
processes. The current concept of transcription factor
functioning is a complex regulatory meshwork of interac-
tions to control pattern and timing of gene expression
during organ development. Transcription factors are known
to play a fundamental role in all levels of heart develop-
ment including cardiac lineage determination, chamber
formation, valvulogenesis, and septation. In this review, we
focus on cardiac transcription factors involved in atrial
partitioning and on those which appeared to be related to
human ASDII. Therefore, we chose four transcription
factor genes and outlined human genetic findings in chro-
nological order of the identification of ASDII-related
defects in men. The time point of the initial identification
of a mutation should always be considered for deducting
frequencies of mutations in a single gene. The total number
of mutations identified is continuously growing due to
mutational analyses in different patient cohorts by com-
petitive research groups once a gene has initially been
found. Regrettably, negative genetic studies are published
only rarely, a fact that further biases a reliable assessment
of mutation frequencies. Considering that the total number
of mutations is continuously growing, the reader is
encouraged to use online databases (such as OMIM) in
order to remain up to date.
TBX5
TBX5 encodes a member of the family of T-box tran-
scription factors and is expressed in embryonic heart and
limb tissues [13]. Mutations in TBX5 produce the Holt–
Oram syndrome (HOS), an autosomal, dominant, highly
penetrant disorder associated with malformations of the
upper limb and CHD (MIM 142900) [33]. Cardiac
malformations are mostly ASDII or ventricular septal
defect (VSD). Genetic ablation of TBX5 in murine
models imposingly recapitulates the human phenotype
[12]. Human mutations in TBX5 were first identified in
1997 by two groups [3, 43] shortly after the chromo-
somal disease locus was mapped to 12q2 [84, 85].
Subsequently, more than 50 germline mutations were
found [1, 8, 9, 16, 28, 31]. A substantial fraction of
TBX5 mutations are deletions, frameshifts or premature
stop codons leading to a presumably dysfunctional pro-
tein. It was proposed that the clinical phenotype depends
on the genetic defect in terms that missense mutations
produce less severe clinical features with accentuation of
the heart (G80R) or upper limbs (R237Q and R237W),
whereas mutations predicted to create dysfunctional
alleles produce substantial malformations in the upper
limb as well as in the heart [4]. Yet, genetic analyses of
a large number of HOS patients indicated that pheno-
types can vary from mild to severe, even among subjects
harbouring identical mutations [10]. Notably, most
mutations found in TBX5 are located in the DNA-
binding T-box domain and a substantial fraction causes
premature stop codons. Therefore, haploinsufficiency is
generally acknowledged to be at the root of HOS.
Interestingly, Postma and colleagues [66] found a gain-
of-function TBX5 mutation in a family with mild limb
and heart phenotypes. Most affected family relatives had
atrial fibrillation in the absence of cardiac malformations,
a finding not uncommon among Holt–Oram patients [49].
Other studies also found dextroposition of the heart and
other extracardiac abnormalities in single patients with
genetically confirmed HOS [89]. The phenotypic spec-
trum of inborn developmental disorders, including CHD,
of HOS patients is likely to be expanded further in
future studies. These findings are interesting as they
allocate insights into relationships between genotypes
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and phenotypes. However, caution should be exercised
when interpreting molecular findings in relation to a
disease phenotype. An overview of mutations found in
TBX5 is given in Fig. 2.
NKX2.5
NKX2.5, a vertebrate homologue of drosophila tinman, is a
homeobox transcription factor highly expressed in early
progenitors and in adult cardiomyocytes [44]. Targeted
disruption of NKX2.5 in rodent models results in early
embryonic lethality due to failed cardiac looping and defects
in chamber formation [46]. Nkx2.5 was the first gene iden-
tified as a relevant disease gene for non-syndromic human
ASDII. In 1998 Schott et al. [73] found two NKX2.5 muta-
tions after mapping a chromosomal locus in families with
ASDII. Most mutation carriers had ASDII associated with
atrioventricular conduction defects, albeit some also had
VSD, tetralogy of Fallot (TOF) or other cardiac abnormali-
ties. Subsequently, Benson et al. [6] identified seven NKX2.5
mutations among 26 thoroughly selected patients with AV
conduction disease and/or CHD. Notably, the authors found
a NKX2.5 missense mutation (R25C) in a TOF patient
without del22q1. A subsequent study noted the same muta-
tion in 3 of 114 patients with TOF as well as in two African-
American control subjects indicating that the variant may
represent an ethnically restricted susceptibility variant over-
represented in patients with TOF [26]. Future studies on
large number of patients including cohorts from different
ethnicities remain to be done to investigate whether R25C
predisposes for CHD in a polygenic setting. A large number
of candidate gene approaches resulted in identification of
more than 30 NKX2.5 mutations to date [22, 25, 29, 32, 35,
36, 42, 50, 60]. It has been proposed that nonsense or frame
shift mutations at any location and all mutations located in
the homeodomain are associated with AV conduction dis-
ease, while patients harbouring missense mutations outside
of the homeodomain show no AV conduction delay [19]. The
function of NKX2.5 in atrial septal development was
highlighted by the study of Biben and colleagues [7]. The
authors analysed morphogenesis of the atrial septum in dif-
ferent mice strains harbouring one defect allele of the
NKX2.5 gene. In comparison to humans harbouring NKX2.5
loss-of-function alleles, only a small subset of NKX2.5
heterozygous mice unmistakably had ASDII, a fact that may
be attributed to the redundant function of murine nkx2.6.
Still, subtle anomalies of the atrial septum like patent fora-
men ovale (PFO) and atrial septal aneurysm (ASA) were
significantly over-represented among NKX2.5 mutant mice
[7]. These observations and phenotypes of inbred mice with
atrial septal lesions [40] suggest a continuum of ASDII to
milder septal anomalies in particular PFO. Nonetheless,
sequence analysis approaches of human NKX2.5 in patients
with PFO have not yet resulted in any identification of
pathogenic variants [5, 22].
GATA4
GATA4 encodes a member of the GATA family of
zinc-finger transcription factors, which recognize (A/T)GATA
(A/G) promotor motives [39]. Mice lacking both
GATA4 alleles die between day 7.0 to 9.5 of embryonic
development and bear no evidence of heart tube formation
[53]. Crispino et al. [20] generated mice harbouring a mis-
sense mutation in a highly conserved zinc-finger domain
(V217G). GATA4-V217G embryos die after heart looping
and reveal cardiac malformation resembling severe CHD in
humans [20]. The role of GATA4 defects in human CHD was
first proposed in 1999. Pehlivan and colleagues [61] inves-
tigated patients with 8p23 syndrome and found GATA4
haploinsufficiency in those with cardiac malformation but
not in a subject with 8p23.1 without CHD. In 2003, Garg
et al. [24] identified the first two families with isolated
congenital cardiac septal defects caused by inherited muta-
tions in the GATA4 gene (G296S and c.1075delG). Sub-
sequent molecular characterization of these mutations
revealed a significantly impaired affinity to promotor DNA
and a failure of GATA4 to interact with TBX5 resulting in a
Fig. 2 Schematic presentation
of mutations found in TBX5 as
a cause for Holt–Oram
syndrome. Mutations are
described at the protein level
according to reference
AAC04619.1. The majority of
mutations are located in the
DNA-binding T-box domain of
TBX5. Intronic and somatic
mutations are not included
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significant reduction of target gene expression in transcrip-
tional assays [24]. One year later, Okubo and colleagues [58]
reported a Japanese family with autosomal, dominant ASDII
due to a heterozygous GATA4 deletion in an adjacent
nucleotide upstream to the frameshift mutation reported by
Garg et al. (c.1074delC). Subsequently, we and others
identified several GATA4 missense mutations particularly in
patients with inherited ASDII [32, 65, 68, 88] but also in
consanguineous patients with TOF [57]. In an attempt to
identify novel GATA4 variants in a large group of CHD
patients and in control subjects without CHD Tomita-
Mitchel and colleagues [88] analysed the coding region by
use of denaturing high-performance liquid chromatography
(WAVE). Interestingly, the authors found a considerable
number of non-coding variants in patients with septal and
conotruncal heart defects but not among control subjects. But
whether or not GATA4 silent variants may predispose to
CHD by altering exonic splice sites remains to be elucidated.
Recently, a variety of GATA4 missense variants were also
noted in different Chinese cohorts [83, 94, 95]. However,
family and functional studies for the establishment of any
pathogenic impact of these variants have not yet been per-
formed. It is noteworthy that some candidate gene approa-
ches which did not result in the identification of pathogenic
mutations were also published [71, 93]. Given the consid-
erable amount of genetic data including NKX2.5 and
GATA4 in CHD patients, one may speculate that the diver-
sity of CHD phenotypes is smaller in patients with GATA4
mutations when compared to those with mutations in
NKX2.5. A graphical summary of ASDII-related GATA4
mutations is given in Fig. 3.
TBX20
TBX20 is an ancient member of the TBX transcription
factor family and is highly expressed in the forming heart
Fig. 3 Schematic
representation of NKX2.5,
GATA4 and TBX20 protein
structure with exonic germline
mutations related to non-
syndromic CHD indicated. All
mutations related to ASDII are
represented on the top.
Mutations found in patients with
CHD other than ASDII are
shown below the structural
domains. All mutations which
were evaluated by family and/or
functional studies are
represented in bold letters.
Mutations which were found in
patients with dilated
cardiomyopathy are marked
with an asterisk. Somatic and
intronic mutations are not
included
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tube and developing valve tissues [80, 82]. TBX20
interacts in regulatory networks with NKX2.5, GATA4
and TBX5 during embryonic heart formation [78]. In
2002 Szeto and colleagues [81] showed that TBX20 is
essential for cardiac chamber formation in zebrafish.
Ablation of TBX20 in murine models was independently
generated by three research groups and showed similar
phenotypic features [16, 75, 79]. TBX20-null embryos
show small heart tubes which fail to undergo looping.
While homozygous knock-out mice die at mid-gestation,
heterozygous animals are viable and exhibit dilation of
cardiac chambers and decreased contractility resembling
human dilated cardiomyopathy [79]. Inherited TBX20
mutations in patients with CHD were first identified in
2007 [41]. Kirk et al. found two TBX20 mutations among
more than 300 patients with various CHD. Interestingly,
one family relative harbouring a loss-of-function allele
(Q195X) had also evidence for dilated cardiomyopathy
indicating that TBX20 haploinsufficiency may predispose
to age-related heart failure convergent with the findings in
heterozygous TBX20 mice [79]. Subsequently, Qian et al.
[67] found three TBX20 missense mutations in young
probands with early onset, familial DCM who showed no
evidence of CHD. In the same study, the authors reported
additional non-synonymous alterations (H186D, L197P)
in patients with isolated ASDII and ASDII in combination
with TOF [67]. Simultaneously, a number of variants
were also found among Chinese patients with ASDII or
TOF [45]. However, functional studies still remain to be
done in order to underpin the pathogenic impact of these
mutations. We have recently identified a TBX20 missense
variant in a patient with cribriform ASDII which results
in a gain of transcriptional function [64]. The synergistic
interactions of TBX20 with co-transcription factors
NKX2.5 and GATA4 were also enhanced and the mutant
T-box showed a significantly increased dynamic structure
[64]. Therefore, one may propose a model in which
TBX20-I121M adopts a more fluid tertiary structure
leading to enhanced or dysregulated interactions with
cofactors and target DNA sequences, and concomitant
disruption of the cardiac gene regulatory network. Nota-
bly, Hammer et al. [30] found a significant upregulation
of TBX20 mRNA in myocardial samples of TOF patients.
The I152M mutation found in the study by Kirk et al.
[41] also revealed increased actin expression in a frog
model. Future studies remain to be done so as to inves-
tigate whether a gain of transcriptional TBX20 activity
may be a common finding in CHD-related mutations. It is
noteworthy that family relatives positive for either gain-
of-function mutations (I152M as well as I121M) had large
ASDII or PFO with permanent shunt instead of ASDII
[41, 64]. Therefore, one may propose that PFO shares a
common genetic basis with ASDII in terms of slightly
reduced, sustained or enhanced transcriptional function of
TBX20.
Genes encoding sarcomeric filaments
Cardiomyocyte architecture is organized by the formation
of the sarcomeres representing the molecular motor of
force generation for heart muscle contraction. The path-
ogenicity of mutations in sarcomeric genes for human
cardiomyopathies is today well accepted [55]. Still, for-
mation of sarcomeric structures also seems to be required
for cardiac development [27] and recent human genetic
data indicate that (at least in some cases) cardiomyopa-
thies and ASDII may share a common genetic aetiology
[51]. Sarcomeric gene mutations were also identified as
being capable of inducing ASDII with left ventricular
non-compaction cardiomyopathy (LVNC) [14, 54]. Mon-
serrat and colleagues genotyped patients with cardiomy-
opathies for one mutation in the alpha-actin gene
(ACTC1) gene that was previously reported in patients
with apical hypertrophy [54]. Surprisingly, the I101K
mutation was found in five unrelated families segregating
with disease status. Among 47 patients harbouring I101K
8 had ASA and ASDII in addition to cardiomyopathy
[54]. The authors proposed that LVNC and hypertrophic
cardiomyopathy may represent overlapping entities.
Moreover, the fact that septal defects were found in five
out of six families harbouring I101K suggested a relation
of the mutant ACTC1 allele with ASDII although muta-
tions in GATA4 or NKX2.5 were not excluded in ASDII
probands. In 2008 Budde et al. [14] identified a large
family with LVNC, Epstein anomaly and ASDII. Linkage
analyses mapped the disease locus on chromosome 14q12,
a region encoding two myosin heavy chain genes (MYH6
and MYH7). Subsequently, the authors identified a MYH7
missense mutation (R281T) segregating with disease sta-
tus in the pedigree [14]. Four relatives harbouring R281T
had ASDII in addition to cardiomyopathy. No mutation in
NKX2.5 or GATA4 was found among them (unpublished
data).
Mutations in sarcomeric genes were also found in
families with ASDII who showed no signs of cardiomy-
opathy [18, 48]. The first evidence indicating that inherited
sarcomeric gene mutation may cause familial ASDII arose
from a linkage study in 2006. Ching et al. [18] identified a
missense mutation in alpha myosin heavy chain (MYH6) in
a family with autosomal, dominant ASDII. MYH6 is a
cardiac-specific sarcomeric gene highly expressed in the
developing atrial septum and is regulated by TBX5. Mor-
pholino-mediated knockdown of MYH6 disrupted atrial
septation in chick embryos. Moreover, the authors found
the I820N mutation to specifically reduce binding affinity
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123
to regulatory light chains [18]. A study by Matsson and
colleagues [48] underpinned the assumption that sarco-
meric genes produce isolated ASDII. The authors presented
two kindreds with familial ASDII harbouring a founder
mutation in the ACTC1 gene (M123V). The M123V
mutation also showed a reduction of binding properties of
ACTC1 for interacting with the thick filaments. Subsequent
analyses of ACTC1 in a large cohort of patients with
mostly sporadic CHD revealed one additional mutation
leading to a severely truncated protein (17-bpDEL c.251).
Indeed, morpholino-mediated knockdown of ACTC in
chick embryos revealed reduced growth of atrial septa
similar to the findings for the MYH6 knockdown [48, 70].
Taken together, the above studies provide intriguing
insights in the role of sarcomeric filaments in cardiac
morphogenesis and atrial septal development. It is note-
worthy that ASDII is by far the type of CHD which was
most frequently found. The human genetic findings
strongly indicate that ASDII may not only be related to
defects in regulatory factors but also to mutations in their
target genes.
Conclusions
In this review article we have attempted to outline previous
and ongoing efforts on research regarding the genetic
pathogenesis of ASDII. Though there are indeed also a
number of genetic factors in ASDII aetiology which we did
not mention here, we have tried to summarize the genes
which were most abundantly investigated and which are, in
our view, intriguing factors for future studies on human
ASDII. Unequivocally, the disease pathogenesis of ASDII
cannot be restricted to a single number of genes given the
complex interaction of genetic environmental networks.
Indeed, it is most likely that the majority of patients with
ASDII have a complex, multifactorial aetiology, with
underlying mechanisms that remain to be elucidated in the
years to come. Large, well-characterized patient cohorts
will be necessary to unravel the minor deleterious impact
of more prevalent gene variants on defects in atrial parti-
tioning. Nevertheless, we feel that the few but invaluable
families harbouring single gene defect mutations related to
ASDII do represent good contact points for researching the
root of human septal development. Inherited, naturally
occurring mutations provide us with the chance to get a
glimpse into the complex genetic mechanisms involved in
human heart development.
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